Vertex Pharmaceuticals (VRTX) Q3 2025 Earnings
Vertex Pharmaceuticals reported Q3 2025 revenue of $3.1B (+11.0% YoY), beat analyst consensus of $3.1B by $16.9M. Diluted EPS came in at $4.80 (+9.6% YoY), beat the $4.57 consensus by $0.23. Vertex Pharmaceuticals reports across 3 business segments, led by Cystic Fibrosis (CF), Hematology and Pain Management, and Specialty Pipeline Programs.
Financial Snapshot
Trailing eight quarters through Q3 2025
Q3 2025 Earnings FAQ
Common questions about Vertex Pharmaceuticals's Q3 2025 earnings report.
Vertex Pharmaceuticals (VRTX) reported Q3 2025 earnings on November 3, 2025 after market close.
Vertex Pharmaceuticals reported revenue of $3.1B and diluted EPS of $4.80 for Q3 2025.
Revenue beat the consensus estimate of $3.1B by $16.9M. EPS beat the consensus estimate of $4.57 by $0.23.
Compared to the same quarter a year prior, revenue grew 11.0% from $2.8B a year earlier and diluted EPS grew 9.6% from $4.38.
You can read the 8-K earnings release (0000875320-25-000230) and the 10-Q periodic report (0000875320-25-000232) directly on SEC EDGAR. The filing index links above go to sec.gov.